Head and Neck Neoplasms D006258

Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Head and Neck Neoplasms

Description

Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)   MeSH

Hierarchy View

Subtype Terms (8)

Esophageal Neoplasms
521 drugs (183 approved, 338 experimental)

Facial Neoplasms
 

Mouth Neoplasms
69 drugs (44 approved, 25 experimental)

Otorhinolaryngologic Neoplasms
3 drugs (2 approved, 1 experimental)

Parathyroid Neoplasms
12 drugs (10 approved, 2 experimental)

Squamous Cell Carcinoma of Head and Neck
519 drugs (155 approved, 364 experimental)

Thyroid Neoplasms
205 drugs (124 approved, 81 experimental)

Tracheal Neoplasms
3 drugs (2 approved, 1 experimental)


Phase 2 Indicated Drugs (156)

Phase 1 Indicated Drugs (138)


Organization Involved with Phase 3 Indications (138)

Organization Involved with Phase 2 Indications (254)

Abbott

Access Pharmaceuticals, Inc.

Adaptimmune

Aduro BioTech

Advanced Clinical Research Inc.

Advaxis, Inc.

Aichi Medical University

Ain Shams University

AIO-Studien-gGmbH

Alder Biopharmaceuticals

Alume Biosciences, Inc.

American Cancer Society, Inc.

AperiSys, Inc

Apices Soluciones S.L.

ArQule

Assistance Publique - Hôpitaux de Paris

Astellas

AurKa Pharma Inc.

Aventis

Azienda Ospedaliera S. Croce e Carle Cuneo

Azienda USL 4 Prato

Badalona Hospital Germans Trias i Pujol

Barretos Cancer Hospital

Bay Hematology Oncology

Baylor University

Biolitec Pharma Ltd.

BioMimetix Pharmaceutical, Inc.

Biontech

Biovitrum AB

Boneca Corporation

Boston University

Brazilian Society of Clinical Oncology

Burzynski Research Institute

Catalysis SL

Cedars-Sinai Medical Center

Centocor

Central South University

Centre Georges Francois Leclerc

Centre Henri Becquerel

Centre Hospitalier de Saint-Brieuc

Centre Jean Perrin

Centre Leon Berard

Centre Paul Strauss

Certus International

Chang Gung University

Chao Family Comprehensive Cancer Center

Chengdu Shi Endor Biological Engineering Technology Co., Ltd

China International Medical Foundation

China Medical University

Chinese Academy of Medical Sciences

Chinese Society of Clinical Oncology

Chonbuk National University

Chonnam National University

Chungbuk National University

Chungnam National University

City of Hope National Medical Center

Clinica Universidad de Navarra

Clinique de l' Estuaire, Pornichet

Clinique Pasteur

Coastal Carolina Radiation Oncology

Commonwealth ENT, Louisville, KY

Cornell University

Covance

CTI BioPharma

Cyprus University of Technology

Department of Defense

Doublle Bioproduct Inc

Drexel University

Duke University

Dynavax Technologies Corporation

Endocyte

Erasmus University Rotterdam

Fondation ARC

Food and Drug Administration

Free University of Brussels

Fudan University

Fundação de Amparo à Pesquisa do Estado de São Paulo

Fundación Hospital Alcorcón

Geisinger Clinic

General Drug House Ltd., Bangkok

General Electric

GenVec

Georgetown University

George Washington University

Government of Canada

Government of Taiwan

Government of Thailand

Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Gruppo Oncologico del Nord-Ovest

Harbin Medical University

Holy Name Medical Center, Teaneck, NJ

Hope Cancer Institute, Inc.

Hospital Duran i Reynals

Huazhong University of Science and Technology

Icahn School of Medicine at Mount Sinai

Ignyta, Inc.

Imclone

Immunomedics

Immunovative Therapies

Incyte

Indiana University

Innate Pharma

Innogene Kalbiotech Pte. Ltd

Innovation Pharmaceuticals

Instituto do Cancer do Estado de São Paulo

Institut Sainte Catherine

IQVIA

Istituto Nazionale per lo Studio e la Cura dei Tumori

Izun Pharma Ltd

James Graham Brown Cancer Center

Jiangsu Cancer Institute & Hospital

Jiao Tong University

Kadoorie Foundation

KhonKaen University

Kom Op Tegen Kanker

Kura Oncology, Inc.

Kuwait Cancer Control Center

Lankenau Hospital

Leiden University

Luzitin SA

Mackay Medical College

Mashhad University of Medical Sciences

Medical University of Ohio

Medical University of South Carolina

Moorgreen Hospital, Southampton

MultiVir, Inc.

Nang Kuang Pharmaceutical Co., Ltd.

National Cancer Center, Korea

National Cheng Kung University

National Comprehensive Cancer Network

National Institute of Dental and Craniofacial Research (NIDCR)

National Institutes of Health (NIH)

National Taiwan University

New Hanover Regional Medical Center

Noble Organisation

Northwestern University

Novartis

Nova Scotia Health Authority

Oncovir, Inc.

Ontario Institute for Cancer Research

OSI Pharmaceuticals

Otsuka

Papworth Hospital NHS Foundation Trust

PDS Biotechnology Corp.

Peking University

Pennsylvania State University

Peter MacCallum Cancer Centre

Pfizer

PharmaEngine

Piramal

Pivotal S.L.

PNP Therapeutics, Inc.

Polyclinique du Parc, 31078 Toulouse, France

Professional Compounding Centers of America

Providence Health & Services

Providence Hospital

Queen's University, Belfast

RxKinetix

SANTELYS

SciClone Pharmaceuticals

SCRI Development Innovations

Seoul National University

Shanghai Henlius Biotech

Shanghai Xuhui District Central Hospital

Shenzhen SiBiono GeneTech Co.,Ltd

Shin Kong Wu Ho-Su Memorial Hospital

Sichuan University

Siemens

Sinocelltech Ltd.

Sound Pharmaceuticals

Southern Illinois University

Spherium Biomed

Stand Up To Cancer

State University of New York

State University of New York, Buffalo

State University of New York, Syracuse

Sucampo

Sungkyunkwan University

SynCore Biotechnology

Tactile Medical

Taipei Medical University

Taipei Veteran General hospital

Tesaro

Theradex

The University of Texas, Dallas

Trial Form Support S.L.

TTY Biopharm

TyrNovo Ltd.

Ubonratchathani Cancer Hospital

UNICANCER

Universidad Autonoma de Barcelona

Universidad Autonoma de Madrid

Universidad Complutense de Madrid

Université catholique de Louvain

University of Alberta

University of Amsterdam

University of Angers

University of Arizona

University of Arkansas

University of California, San Diego

University of California, San Francisco

University of Cantabria

University of Cincinnati

University of Colorado, Denver

University of Connecticut

University of Duesseldorf

University of Florence

University of Florida

University of Granada

University of Groningen

University of Helsinki

University of Illinois at Chicago

University of Iowa

University of Kansas

University of Kentucky

University of Lausanne

University of Lille

University of Limoges

University of Ljubljana

University of Louisville

University of Lyon

University of Malaga

University of Maryland

University of Medicine and Dentistry of New Jersey

University of Missouri

University of Montpellier

University of Nice Sophia Antipolis

University of North Carolina at Chapel Hill

University of Oklahoma

University of Oslo

University of Paris

University of Picardie Jules Verne

University of Pittsburgh

University of Poitiers

University of Salamanca

University of Santiago

University of Sao Paulo

University of South Carolina

University of Southern Denmark

University of Tennessee

University of Texas, San Antonio

University of Turku

University of Ulsan

University of Utah

University of Valencia

University of Vermont

University of Western Ontario

University of Wisconsin

University of Zaragoza

Val d'Aurelle Cancer Institute

V Foundation

Washington University in St. Louis

Yonsei University

Organization Involved with Phase 1 Indications (74)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.